For two consecutive weeks, Iran Pharma and Pharmax 2021 exhibitions were held in Tehran, and Tofigh Daru, as the largest knowledge-based and engineering research company in the country, had a successful presence in these two exhibitions.
Tawfiq Daroo at Pharmax Festival, which is the place of emergence and emergence of capabilities of the effective pharmaceutical material industry, was able to be introduced as a top company in the field of "API Award" by unveiling new products effective in the treatment of corona.
At Farmax 2021, Tofigh Drug unveiled its new drug, Molnopiravir, as the first specific oral drug to treat coronary artery disease, which also affects new mutations and strains of the Covid virus.

At Farmax 2021, Tawfiq Drug unveiled its new drug, Molnopiravir, as the first specific oral

drug to treat coronary artery disease, which also affects new mutations and strains of the Covid virus.

Merck Company has produced this drug and Tawfiq Drug will be ready to supply it in the country's pharmaceutical market immediately after obtaining the international license of this drug by Merck Pharmacy 

The synthesis of the active ingredient and the final formulation and production of monopiravir on an industrial scale started last year in this Daneshbanian company and now the steps of obtaining a production license in the Food and Drug Administration are being followed.
In different visits to these two special exhibitions of the country's pharmaceutical industry, Mohammad Ali Zolfi Gol, Minister of Science, Research and Technology, Saeed Omrani, Deputy Attorney General and representatives of the General Inspection Organization paid a special visit to Tawfiq Daroo booth while expressing surprise and satisfaction with the production. Technologically, this research and engineering group in the fields of cancer, diabetes and corona treatment, and congratulating the remarkable successes of this company, announced their comprehensive support for domestic production and disinfection.